A total of 267 families with two or more siblings with multiple sclerosis (MS) were genotyped with 14 restriction fragment length polymorphisms at the TCR b locus. A nonparametric linkage analysis of the data showed no evidence for linkage to this locus (mlod ¼ 0.11). No significant allelic or haplotype transmissions were observed in the total sample of 565 patients. After stratification for the presence of HLA DRB1*15, an association was observed between the BV25S1*1-BV26S1*1-BV2S1*1 haplotype and MS (P ¼ 0.00089). This was not significant upon correction for multiple comparisons. It was also not significant when the haplotype frequency in affected individuals was compared to a normal control sample (P ¼ 0.77). Furthermore, the associated haplotype was followed-up in an independent sample of 97 nuclear families with a single DRB1*15-positive child with MS. The BV25S1*1-BV26S1*1-BV2S1*1 haplotype did not show significant evidence for transmission distortion but the same trend was seen (P ¼ 0.21). There were no significant associations observed in the DRB1*15-negative patients and no detectable difference was seen in the DRB1*15-positive BV25S1*1-BV26S1*1-BV2S1*1 association when comparing different subgroups based on clinical course of MS. These results show no evidence for linkage and fail to establish an association between MS susceptibility and the TCR b locus.
Introduction
The T-cell receptor (TCR) is a heterodimeric glycoprotein responsible in part for T-cell recognition of epitopes presented by HLA molecules. The TCR is composed of two pairs of polypeptide chains, a and b, the genes for which are located on chromosome 14q and 7q35 respectively. Because of their immune-related function and their interaction with HLA antigens, the T-cell a and b receptor genes have been candidates for susceptibility to autoimmune disease.
Despite an initial positive association of a TCR a rearrangement in multiple sclerosis brains (MS), 1 most studies have failed to demonstrate an association with germline polymorphisms and MS. 2, 3 The same is not true for the TCR b receptor variable chain locus. The locus has been linked to MS in a small sample of affected sibs, 4 and an MS genome scan observed evidence for increased haplotype sharing at 7q35. 5 However, the finding is not consistent as other groups have not found linkage in the same region. [6] [7] [8] Case-control studies involving TCR b polymorphisms have reported associations with MS, [9] [10] [11] [12] with other positive associations observed once the samples were stratified for the presence of HLA DR2 antigens. 13, 14 This stratification has been extended to include those patients who are DR2 positive and suffering from a relapsingprogressive course of multiple sclerosis. 15 This suggests that the TCR b polymorphisms may contribute to the expression of MS. Similar to the TCR linkage analysis results, many other research groups have failed to confirm a significant association. [16] [17] [18] [19] [20] [21] The reasons for these discrepant results are many and may include population stratification, small sample sizes, clinical heterogeneity within the MS patient sample, informativity of the selected markers or simply the reporting of false-positive results. 22 The low reproducibility of positive genetic association studies has drawn appropriate comment. 23 
Results
To investigate the evidence for linkage and association of TCR b with MS, we have genotyped a panel of biallelic polymorphisms within the TCR variable region in a sample of MS families and normal controls. By using a family-based, multitiered approach, the false-positive findings that result from population stratification and multiple comparisons should be minimized.
Nonparametric linkage results
For the 333 affected sib pairs derived from 267 families, we found a multipoint mlod score of 0.11. for the marker BV21S4 (Table 1 ). In the total sample, we can exclude a locus (LODoÀ2) contributing a l locus 1.7. There was no evidence for increased sharing in the sibling pairs that are DRB1*15 positive or negative (Table 1) .
Transmission disequilibrium results
The transmission disequilibrium test (TDT) results for each marker are presented in Web Table 1 A 'sliding-window' TDT analysis was performed for haplotypes across three loci at a time in order to increase the number of informative parents for the TDT. The choice of a three-locus haplotype is an arbitrary one.
Only two of the three-locus haplotypes assessed in the total sample showed a significance value Po0.05, although a number of the other haplotypes (7/39) did show a trend (0.05oPo0.10) for transmission distortion from heterozygous parents ( Table 2) . Only the haplotypes with the greatest w 2 value and over 5% in frequency per tri-locus interval are presented in Table 2 .
The allele frequencies of the markers in the affected individuals were also compared to the allele frequencies in the sample of 179 normal controls (Web Table 2 , see Supplementary Information). Only one randomly selected affected offspring per family was used for this analysis. In the total sample, only marker BV12S2 had a significance value less than Po0.05. This P-value lost its significance when the multiple comparisons inherent in testing the many alleles were taken into account. No findings were significant when three-locus haplotypes were considered.
Results for the sample stratified by the presence of DRB1*15 A number of previous studies have observed an MS association with TCR polymorphisms upon stratification for DRB1*15 status. 9, 14 Given these previous findings and the knowledge of the HLA-TCR functional interaction, 24 we also tested an association, stratifying for the presence of HLA DRB1*15. The TDT results for each marker stratified for the presence of DRB1*15 in the affected offspring are given in Web Table 3 (see Supplementary Information). BV8S3 showed an overtransmission of allele 1 with 117 transmissions compared to 79 nontransmissions (w 2 ¼ 7.37, P ¼ 0.0068). However, the corrected P-value was not significant.
In the three-locus haplotype TDT analyses, 20 of the 39 tri-locus haplotypes (with frequency greater than 5%) had uncorrected significance values less than 0.05 ( Table 3 ). The most significant finding was for the *1-*1-*1 haplotype of the BV25S1-BV26S1-BV2S1 loci. The haplotype was transmitted 73 times and not transmitted 38 times (w 2 ¼ 11.04; P ¼ 0.00089). This finding is not significant with a conservative Bonferroni correction.
For the case-control study design, there were 43 DRB1*15-positive normal controls compared to 167 DRB1*15-positive patients. Only one DRB1*15-positive patient was chosen per sibling pair family. The allele frequencies for the 14 markers were not significantly different between the two groups-see Web Table 4 (Supplementary Information). As no differences were observed in allele and haplotype frequencies between the DRB1*15-positive and DRB1*15-negative normal control samples, the groups were combined and the analysis repeated. BV12S2 and BV6S5 showed mild associations (P ¼ 0.03 and 0.02, respectively); however, they were not significant with correction (Web Table 4 , see Supplementary Information).
There were also no three-locus haplotype frequencies differing between the DRB1*15-positive normal controls and MS patients (data not shown). The haplotype frequency of BV25S1*1-BV26S1*1-BV2S1*1 in MS patients was 53% (177/334) and not significantly different from the frequency observed in normal controls. In fact, the frequency of the BV25S1*1-BV26S1*1-BV26S1*1 haplotype in the MS patients was lower than the unaffected sample at 57.5% (206/358) and the DRB1*15-positive normal controls at 58% (50/86).
Follow-up of BV25S1*1-BV26S1*1-BV2S1*1 in an independent sample There was evidence for transmission distortion of the BV25S1*1-BV26S1*1-BV2S1*1 in the DRB1*15-positive offspring; however, the result was not significant upon correction for multiple comparisons and we did not observe an increased frequency of the haplotype in individuals with MS (53%) compared to an unaffected population (58%). Nevertheless, we have followed-up the finding in an independent sample of 97 nuclear families each with one DRB1*15-positive child with MS. There was a total of 176 parents from which to assess transmission to these 97 offspring and only the BV25S1, BV26S1 and BV2S1 loci were genotyped. The BV25S1*1-BV26S1*1-BV2S1*1 haplotype was transmitted 19 times and not transmitted 12 times (w 2 ¼ 1.58, P ¼ 0.21).
Results for the sample stratified by the absence of DRB1*15 TDT was also examined in those MS patients that were DRB1*15-negative (n ¼ 233). There were no uncorrected significance values less than 0.05 (Web Table 5 , see Supplementary Information). In a three-locus TDT analysis, there was also no significant transmission distortion ( Table 4 ). The BV25S1-BV26S1-BV2S1 haplotype did show overtransmission of the *1-*2-*2 haplotype (35 times vs 26 times), but this was not significant ( Table 4 ). The *1-*1-*1 haplotype was transmitted 34 times and not transmitted 44 times in the DRB1*15-negative offspring. Not unexpectedly, this was significantly different from the 73-38 times observed for the BV26S1*1-BV25S1*1-BV2S1*1 haplotype in the DRB1*15-positive offspring (w 2 ¼ 9.17, P ¼ 0.0025). When comparing the allele frequencies between DRB1*15-negative patients and normal controls, the DRB1*15-negative sample showed no Pp0.05 (Web Table  6 , see Supplementary Information).
In the DRB1*15-negative offspring, there were 70 who were DRB1*17 positive. TDT was also assessed in this subgroup of offspring as the DRB1*17 allele is also associated with MS in the Canadian population. There were no significant TCR b associations with Po0.05. Transmission of three-locus haplotypes to DRB1*17-positive DRB1*15-negative patients was also tested and no significant (upon Bonferroni correction) associations were observed.
TCR and linkage disequilibrium
Linkage disequilibrium was observed among the 14 markers tested. The average linkage disequilibrium observed for all pairs tested was D 0 ¼ 0.53 and 71 of the 91 comparisons had Po0.001.
TDT and clinical course TDT was performed in the total sample stratifying by clinical course. There were 224 patients with relapsingremitting MS, 70 with a relapsing-progressive form of MS, 107 with primary chronic progressive MS and 42 with a benign form of MS. There were few significance values less than Po0.05 and none when taking into account multiple comparisons in the total sample. When looking at the DRB1*15-positive subgroup of patients of differing clinical types, the most significant finding was for haplotype BV25S*1-BV25S1*1-BV2S1*1 in the relapsing-remitting patients (transmitted 35 times vs 15 times; w 2 ¼ 8.0, P ¼ 0.0046) and BV24S1*2-BV25S1*1-BV26S1*1 (transmitted 39 times vs 16 times; w 2 ¼ 9.62, P ¼ 0.0019). Although the sample size was much smaller, the same haplotypes were also over-transmitted in the relapsing progressive patients (nine times vs five times for BV25S*1-BV25S1*1-BV2S1*1, and nine times vs seven times for BV24S1*2-BV25S1*1-BV26S1*1). In the primary chronic progressive patients, the same haplotypes were overtransmitted (nine times vs five times for BV25S*1-BV25S1*1-BV2S1*1, and 10 times vs 6 times for BV24S1*2-BV25S1*1-BV26S1*1).
The allele frequencies of the patients with different clinical forms of MS were compared to one another to assess if there were any differences associated with expression of MS. There was no significant difference between the four groups for the 14 markers tested. To further test this hypothesis, we compared the allele frequencies in the more progressive form of the disease (primary chronic progressive) and compared this to the clinical course with a mild clinical course (benign). Again, no significant differences were observed for all 14 markers.
Discussion
There are many diseases associated with the major histocompatibility complex (MHC) and it has been widely believed that allelic association in the region of TCR b could occur as a result of the polymorphisms related to antigen presentation. Accordingly the TCR, as part of the trimolecular complex, has been a candidate for explaining the genetic component of susceptibility.
Polymorphisms of the variable region of the TCR locus have been extensively investigated with conflicting results. Many past studies were not family-based and the results may be prone to mismatching of cases and controls while others have too small numbers to detect a mild-moderate association. 22 Here we used a familybased and case-control study design in tandem and found no evidence for linkage, no evidence for association in the case-control study design and some mildly suggestive, but not significant, evidence for transmission distortion in a subset of patients.
No evidence for linkage was observed in the sample of 333 MS sibling pairs. A locus contributing a l locus ¼ 1.7 can be excluded from operating in this region. These findings contrast with the results of previously published studies 4, 5, 25 as well as a recent Swedish investigation that observed some mild increased sharing in 80 Swedish sibling pairs at the TCR locus. 26 We also do not observe any significant association of TCR b polymorphisms with MS. However, we did find suggestive evidence of a haplotype preferentially transmitted to affected, DRB1*15-positive offspring. The evidence for transmission distortion was observed by TDT in a three-locus analysis but was not significant given the 104 TDT comparisons tested. Since the frequency of this haplotype in normal controls was higher than in affected individuals, this finding can only be considered a potential candidate for future studies in independent samples. By doing so, the penalty for multiple comparisons can be avoided. We performed this strategy in a modest, independent sample of 97 DRB1*15-positive offspring. The BV25S1-BV26S1-BV2S1 loci were genotyped and only BV25S1*1-BV26S1*1-BV2S1*1 was tested for transmission distortion. The haplotype was overtransmitted but not significantly so (transmitted 19 times vs 12 times). The three loci do map to a previously reported restriction enzyme defined region of association, 10 and further investigation is warranted.
We saw no significant differences in the transmission distortion by clinical course in the total sample or in those stratified by DRB1*15 status. Clinical heterogeneity has been a proposed explanation for the contradictory results observed in previous TCR association studies. 19 The transmission ratio in relapsing-remitting patients for the BV25S1*1-BV24S1*1-BV2S1*1 haplotype was comparable to the relapsing-progressive and primary chronicprogressive patients. This contrasts with Hockertz et al, 15 who propose that the TCR b association is present in the relapsing-progressive patients only and that the TCR b polymorphisms have an effect on expressivity of MS. We do not observe any results that support this hypothesis. To conclude, we find no evidence that TCR variable receptor polymorphisms are linked with susceptibility to multiple sclerosis. We find no significant association, but definitive exclusion will require additional study and our findings point to specific haplotypes to test.
Materials and methods

Subjects
The families studied here were ascertained as part of the Canadian Collaborative Project on the Genetic Susceptibility to Multiple Sclerosis (CCPGSMS). In total, there were 565 affected individuals from 267 families studied. A sample of unaffected, Caucasian Canadians was also collected (n ¼ 179). Clinical status was determined according to the Poser criteria. 27 The Canadian Collaborative Projects Database was used to obtain the clinical course information. For this analysis, clinical information from a total of 443 affected subjects (78.4%) were available for stratification analyses.
Genotyping
The individuals from the sibling pair families and the unaffected controls were genotyped for 14 restriction fragment length polymorphisms (RFLPs) spanning the TCR b locus (Figure 1) . The RFLPs used for the study were those characterized by Wei et al, 28 and the nomenclature specified in that and subsequent publications 28, 16 has been used. Figure 1 is a modified map of the TCR b locus derived from the IMGT website (http:// www.ebi.ac.uk/imgt) and is similar to published maps. 11 The PCR conditions for the 14 markers are as described in Wei et al, 16 and incubation with 10 units of enzyme occurred overnight to ensure complete digestion. Digested products were run on 2-4% gels and visualized with UV light. The shorter, 'cut' amplicon was given the allele designation of '1' and the undigested product allele '2'. Low-resolution allele-specific amplification was performed to genotype the HLA DRB1 locus. 29 
Statistical analysis
The sib_ibd and the sib_tdt programs of the Aspex statistical package were used for the linkage and the single-point TDT analysis (www.lahmed. stanford.edu/ pub/aspex). The test for transmission disequilibrium (TDT) counts the number of times an allele is transmitted from heterozygous parents to affected offspring. 30 Genehunter 2.0 was used for the three-locus TDT analysis. 31 Haplotype frequencies when phase was unknown were generated with PHASE 2.0. 32, 33 This is Bayesian method that allows the use of a priori expectations to reconstruct haplotypes. 32 ,33 w 2 tests were performed for the singlelocus case-control tests as described by Zar, 34 and the permutation test function of PHASE 2.0 was used to test for differences between three-locus haplotypes.
A total of 104 TDT and 130 case-control comparisons were performed in the sibling pair and normal control samples. To correct for the multiple comparisons, a Bonferroni correction was applied. Linkage disequilibrium was assessed with the program GOLD. 35 
